BioNTech's first late-stage cancer trial success Phase III trial shows BNT323 slows HER2-positive breast cancer progression, companies say Companies compete with AstraZeneca-Daiichi alliance For COVID ...

FRANKFURT (Reuters) -BioNTech and its partner Duality Biologics said on Friday that a late-stage trial testing their precision drug against a certain type of breast cancer reached its main goal of ...

BioNTech and DualityBio are seeking the Chinese approval of trastuzumab pamirtecan after it outperformed Roche’s Kadcyla (trastuzumab emtansine) in a Phase III breast cancer trial. In an interim ...